OCS

+ Watchlist + Portfolio

Oculis Holding AG

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.57
52-Week Range: $10.52 – $34.48
Market Cap: $729.64M
P/E (TTM): —
EPS (TTM): -1.65
Dividend Yield: —

Advanced Metrics

Price/Book: 3.00
PEG Ratio: —
Return on Equity: -43.70%
Return on Assets: -24.95%
Gross Margin: 0.00%
Operating Margin: -7602.58%
Profit Margin: 0.00%
Current Ratio: 8.35
Debt/Equity: 0.01
Total Debt: $2.54M
Free Cash Flow: $-41.37M
Revenue Growth: 18.80%
Earnings Growth: —
Enterprise Value: $585.38M

OCS Income statement, annual periods, in CHF
CHF	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$22.22M	$29.25M	$52.08M	$57.09M
Selling, General & Admin	$6.74M	$14.72M	$18.92M	$23.20M
Operating Expenses	$32.38M	$45.85M	$73.20M	$81.67M
Operating Income	-$32.38M	-$45.85M	-$73.20M	-$81.67M
EBITDA	-$31.90M	-$87.09M	-$84.89M	-$97.76M
Pretax Income	-$38.64M	-$88.69M	-$85.94M	-$99.14M
Income Tax	$55.00K	$107.00K	-$160.00K	-$186.00K
Net Income	-$38.70M	-$88.80M	-$85.78M	-$98.96M
Diluted EPS	-11.32	-2.97	-2.12	-1.89
Diluted Shares	32.73M	29.90M	40.41M	52.24M

OCS Balance Sheet statement, annual periods, in CHF
CHF	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.79M	$38.33M	$27.71M	$81.33M
Receivables	$1.08M	$1.20M	$1.51M	$1.79M
Current Assets	$23.66M	$101.02M	$104.90M	$218.89M
Total Assets	$37.06M	$114.35M	$120.35M	$235.96M
Current Liabilities	$12.02M	$19.09M	$44.23M	$36.75M
Long-Term Debt	$122.45M	—	—	—
Total Debt	$633.00K	$605.00K	$1.18M	$2.31M
Total Liabilities	$135.05M	$20.63M	$46.97M	$39.89M
Retained Earnings	-$110.98M	-$199.78M	-$285.56M	-$384.51M
Shareholders' Equity	-$97.99M	$93.73M	$73.38M	$196.07M
Working Capital	$11.64M	$81.93M	$60.66M	$182.14M
Net Debt	$102.66M	—	—	—

OCS Cash Flow statement, annual periods, in CHF
CHF	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$25.07M	-$55.04M	-$48.92M	-$66.30M
Capital Expenditure	-$3.55M	-$48.00K	-$230.00K	-$1.39M
Free Cash Flow	-$28.62M	-$55.09M	-$49.15M	-$67.69M
Depreciation & Amortisation	$299.00K	$287.00K	$406.00K	$546.00K
Stock-Based Compensation	$804.00K	$3.61M	$9.78M	$16.04M
Investing Cash Flow	-$3.55M	-$52.97M	-$16.08M	-$60.93M
Financing Cash Flow	$1.71M	$129.63M	$53.98M	$186.92M
Dividends Paid	—	$0.00	$0.00	$0.00
Net Change in Cash	-$26.91M	$21.62M	-$11.03M	$59.68M

OCS Income statement, quarterly periods, in CHF
CHF	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$14.77M	$14.91M	$14.12M	$13.29M	$14.05M
Selling, General & Admin	$4.92M	$5.43M	$5.94M	$6.90M	$7.18M
Operating Expenses	$19.97M	$20.77M	$20.30M	$20.63M	$21.73M
Operating Income	-$19.97M	-$20.77M	-$20.30M	-$20.63M	-$21.73M
EBITDA	-$32.84M	-$25.10M	-$16.53M	-$23.30M	-$28.62M
Pretax Income	-$33.21M	-$25.40M	-$16.84M	-$23.70M	-$28.95M
Income Tax	$7.00K	-$24.00K	$13.00K	-$182.00K	-$98.00K
Net Income	-$33.21M	-$25.38M	-$16.86M	-$23.51M	-$28.85M
Diluted EPS	-0.69	-0.49	-0.32	-0.42	-0.49
Diluted Shares	48.26M	52.29M	52.36M	55.99M	58.91M

OCS Balance Sheet statement, quarterly periods, in CHF
CHF	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$59.87M	$64.27M	$46.44M	$81.33M	$64.56M
Receivables	$2.56M	$2.45M	$2.31M	$1.79M	$1.58M
Current Assets	$188.79M	$166.20M	$150.91M	$218.89M	$227.04M
Total Assets	$204.17M	$181.62M	$167.84M	$235.96M	$243.99M
Current Liabilities	$39.45M	$36.55M	$33.73M	$36.75M	$43.86M
Total Debt	$1.10M	$1.03M	$2.47M	$2.31M	$2.25M
Total Liabilities	$41.55M	$38.52M	$37.24M	$39.89M	$47.34M
Retained Earnings	-$318.77M	-$344.15M	-$361.00M	-$384.51M	-$413.37M
Shareholders' Equity	$162.63M	$143.10M	$130.59M	$196.07M	$196.65M
Working Capital	$149.34M	$129.65M	$117.18M	$182.14M	$183.17M

OCS Cash Flow statement, quarterly periods, in CHF
CHF	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$18.96M	-$17.24M	-$13.42M	-$16.68M	-$15.34M
Capital Expenditure	-$1.10M	-$126.00K	-$124.00K	-$38.00K	-$7.00K
Free Cash Flow	-$20.06M	-$17.37M	-$13.54M	-$16.72M	-$15.34M
Depreciation & Amortisation	$123.00K	$113.00K	$152.00K	$158.00K	$154.00K
Stock-Based Compensation	$2.63M	$4.54M	$4.56M	$4.31M	$5.00M
Investing Cash Flow	-$51.51M	$25.78M	-$2.60M	-$32.62M	-$25.52M
Financing Cash Flow	$103.83M	$605.00K	-$1.71M	$84.19M	$23.60M
Dividends Paid	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	$33.36M	$9.14M	-$17.72M	$34.90M	-$17.25M

Market Snapshot

About

Oculis Holding AG is an ophthalmic biopharmaceutical company developing innovative treatments for eye diseases including diabetic macular edema and dry eye disease.